NetScientific PLC (AIM:NSCI) shares added another 20% on Friday, bringing its total returns for the week above 30%.
The rally comes in a week that saw portfolio company PDS Biotechnology Corporation (NASDAQ:PDSB) announce that preclinical studies on its investigational platform Infectimune showed that Infectimune can generate a broad immune response against viruses such as SARS-CoV-2 and influenza.
Results were published in the Viruses peer-reviewed journal.
NetScientific shares were changing hands at 79.30p with a market capitalisation of £18.6mln as of 1.30pm on Friday.